Skip to main content
. 2023 Apr 19;115(7):831–837. doi: 10.1093/jnci/djad070

Figure 1.

Figure 1.

Flowchart of inclusion for poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi)-treated patients. Acute kidney injury (AKI) was defined as at least a 1.5-fold rise in serum creatinine (SCr) from baseline in the 12 months following PARPi initiation. ESKD = end-stage kidney disease.